EICHORCondition: Atrial Fibrillation · Heart Failure · Sponsor: Aalborg University Hospital
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The DanAblate-HF trial will investigate whether early catheter ablation treatment for atrial fibrillation in patients with heart failure is superior to standard treatment.
This description comes directly from the study's public registry record.
Anne-Christine Ruwald, MD, PhD · +45 40177181 · anne.christine.huth.ruwald@regionh.dk
Sam Riahi, MD, PhD · sar@rn.dk
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. HF patients with AF within the past 12 months HF is defined as all of the below (all must apply) * Clinically assessed Heart Failure with Reduced Ejection Fraction (HFrEF) * An indication for initiation or ongoing guideline directed medical therapy for HFrEF, according to current Heart Failure guidelines * LVEF \< 50% at any point during the past 12 months AF is defined as one or more of the following: A. Symptomatic AF, documented by ECG, Holter of CIED B. Asymptomatic AF with one or more of the following: * Clinical indication for rhythm or rate control (documented by ECG, telemetry, Holter, CIED) * ≥2 ECG detected AF episodes within 3 months (on separate dates) * Holter detected AF with a continuous duration of more than 6 hours * CIED detected AF with continuous duration \>24 hours 2. 18 years ≤ Age \<80 years 3. Optimal medical therapy for HFrEF or planned/current uptitration in guideline directed medical therapy for HFrEF 4. Treatment with anticoagulation for stroke prevention, initiated according to guidelines for treatment of AF Exclusion Criteria: 1. Life-expectancy \< 1 year 2. BMI \> 40 3. Contraindications or unacceptable side effects to rate limiting drugs AND amiodarone 4. LA size (indexed for BSA) \> 60 ml/m2 (volume) on echo within the last year 5. Documented persistent/permanent AF \> 1 year 6. Previous AF ablation/surgery 7. Reversible causes of AF (including, but not limited to, infection within 14 days, untreated thyroid disease, surgery) 8. Severe valvular disease 9. Acute myocardial infarction, cardiothoracic surgery or stroke within the past 3 months 10. Planned cardiothoracic surgery 11. Listed for heart transplant 12. Contraindications for anticoagulation therapy or catheter ablation 13. Severe kidney disease (CKD≥5) 14. Pregnancy 15. Patient unwilling to try medical therapy for AF 16. Patient unwilling/unable to give informed consent for study participation
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Aalborg University Hospital, Department of Cardiology | Aalborg, Denmark | Recruiting |
| Aarhus University Hospital | Aarhus, Denmark | Not Yet Recruiting |
| Department of Cardiology, Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Department of Cardiology, Herlev-Gentofte University Hospital | Hellerup, Denmark | Recruiting |
| Department of Cardiology, Odense University Hospital | Odense, Denmark | Not Yet Recruiting |
| Department of Cardiology, Zealand University Hospital | Roskilde, Denmark | Not Yet Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06560047